Epoetin Alfa
- TRADE NAMES: Binocrit; Epogen (Amgen); Epoxitin; Eprex (Janssen-Cilag); Erypo; Procrit (Ortho)
- INDICATIONS: Anemia
- SYNONYM: erythropoietin; EPO
- CLASS: Erythropoiesis-stimulating agent (ESA), Erythropoietin
- HALF-LIFE: 4–13 hours (in patients with chronic renal failure)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric